Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 7:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 1,144 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Grippe Clear all

Conditions: Influenza, Vaccination
Interventions: Behavioral economics framed test messaging; Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 6 Months and older
Enrollment: 100,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Healthy
Interventions: Influenza vaccination; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 6 Months and older
Enrollment: 147,494 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 187
States / cities: Birmingham, Alabama • Daphne, Alabama • Montgomery, Alabama + 167 more

Conditions: Influenza
Interventions: Flublok, Flucelvax, Fluarix, Fluzone, Fluzone High-Dose; Biological
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 944 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Portland, Oregon • Temple, Texas

Conditions: Influenza, Human
Interventions: aQIV or aTIV, QIV or TIV; Biological
Lead sponsor: Seqirus; Industry
Eligibility: 65 Years and older
Enrollment: 38,769 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 111
States / cities: Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 96 more

Conditions: Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Clinical Stage IIA Cutaneous Melanoma AJCC v8, Clinical Stage IIB Cutaneous Melanoma AJCC v8, Clinical Stage IIC Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma
Interventions: Ipilimumab, Nivolumab, Pembrolizumab, Quadrivalent Inactivated Influenza Vaccine, Resection, Nivolumab + Relatlimab; Biological · Procedure
Lead sponsor: Carlo Contreras; Other
Eligibility: 18 Years to 99 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Influenza
Interventions: Influenza Virus Vaccine, Fluzone®; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 11 Months to 14 Months
Enrollment: 173 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 5
States / cities: Layton, Utah • Pleasant Grove, Utah • Provo, Utah + 2 more

Conditions: Influenza
Interventions: Influenza A/H7N7 Vaccine, Placebo; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 126 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Influenza
Interventions: VAX125; Biological
Lead sponsor: VaxInnate Corporation; Industry
Eligibility: 65 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 3
States / cities: Lanexa, Kansas • Rochester, New York • Charleston, South Carolina

Conditions: Influenza Vaccine, Papillomavirus Infection, Pertussis
Interventions: Vaccination Program; Other
Lead sponsor: Duke University; Other
Eligibility: 12 Years to 26 Years · Female only
Enrollment: 3,988 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 4
States / cities: Burlington, North Carolina • Durham, North Carolina • Raleigh, North Carolina

Conditions: Influenza, Human, SARS-CoV-2 Infection, COVID-19
Interventions: BNT162b2 (Omi XBB.1.5)/RIV, BNT162b2 (Omi XBB.1.5), RIV, Normal saline placebo; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years and older
Enrollment: 644 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 30
States / cities: Lake Forest, California • Tustin, California • Walnut Creek, California + 22 more

Conditions: Seasonal Influenza
Interventions: Planning Prompt, Control Condition; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 3,272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Influenza
Interventions: NanoFlu, Fluzone HD - Day 0, Fluzone HD - Day 21, Saline - Day 21; Biological · Other
Lead sponsor: Novavax; Industry
Eligibility: 60 Years and older
Enrollment: 330 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 3
States / cities: Raleigh, North Carolina • Rocky Mount, North Carolina • Statesville, North Carolina

Conditions: Influenza
Interventions: Nitazoxanide, Placebo; Drug
Lead sponsor: Romark Laboratories L.C.; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 624 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Elmira, New York

Conditions: Influenza
Interventions: Influenza virus vaccine (Pediatric formulation); Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 6 Months to 36 Months
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Influenza, Influenza-like Illness, Influenza Vaccines
Interventions: Egg based influenza vaccines, Recombinant influenza vaccines, Cell-culture based influenza vaccines; Biological
Lead sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine; Other
Eligibility: 18 Years and older
Enrollment: 15,448 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2026
U.S. locations: 9
States / cities: San Diego, California • Annapolis, Maryland • Bethesda, Maryland + 5 more

Conditions: Influenza, Virus Diseases
Interventions: H5N1 (6-2) AA ca Recombinant (A/VietNam/1203/2004 x A/AnnArbor/6/60/ca); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Influenza
Interventions: Low dose, Intermediate dose, High dose, Placebo; Biological
Lead sponsor: KBio Inc; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Influenza Immunization, Healthy Volunteers
Interventions: Quadrivalent Inactivated Influenza High Dose, COVID-19 mRNA Vaccine (nucleoside modified); Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 65 Years and older
Enrollment: 306 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 6
States / cities: Glendale, Arizona • San Diego, California • Vista, California + 3 more

Conditions: Influenza
Interventions: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Mesa, Arizona

Conditions: COVID-19 Prevention
Interventions: Ad26.COV2.S, Placebo, Influenza Vaccine; Biological · Other
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 18 Years and older
Enrollment: 861 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 17
States / cities: Tempe, Arizona • San Diego, California • Coral Gables, Florida + 12 more

Conditions: Influenza A Virus Infection
Interventions: Collection of Anti-Influenza A Immune Plasma; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 59 Years · Male only
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2019
U.S. locations: 2
States / cities: San Diego, California • Bethesda, Maryland

Conditions: COVID-19 Immunization, Influenza Immunization
Interventions: RIV (recombinant influenza vaccine), rC19 (dose 1), RIV + rC19 (dose 1), RIV + rC19 (dose 2), RIV + rC19 (dose 3), RIV + rC19 (dose 4), Placebo (0.9% NaCl); Biological · Other
Lead sponsor: Sanofi; Industry
Eligibility: 50 Years and older
Enrollment: 980 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 12
States / cities: Phoenix, Arizona • Cerritos, California • Vista, California + 9 more

Conditions: Influenza, Healthy
Interventions: Bivalent influenza vaccine, Placebo; Biological · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 2
States / cities: Stockbridge, Georgia • Portland, Oregon

Conditions: Influenza A, Influenza Type B, SARS CoV 2 Infection, RSV Infection
Interventions: Diagnostic Test for identification of influenzas A, influenzas B, RSV and SARS-CoV-2 infections; Diagnostic Test
Lead sponsor: Baebies, Inc.; Industry
Eligibility: Not listed
Enrollment: 2,500 participants
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Raleigh, North Carolina

Search by objective public record fields.

Kaiser Colorado Flu Nudge

A Study to Describe Pediatric Influenza Vaccine Coverage

Immunogenicity Trial of Egg- Versus Non-Egg-Based Influenza Vaccines Among HCP

A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age

Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma

Safety and Immunogenicity of Fluzone® Vaccine in Children Who Received 2 Doses of the 2005-2006 Fluzone Formulation.

Safety, Reactogenicity, and Immunogenicity of Inactivated Influenza A/H7/N7 Vaccine in Healthy Adults

Safety and Immunogenicity of VAX125 Influenza Vaccine in Community-living Adults >= 65 Years of Age

Effectiveness of a Vaccination Program in the Community Ob/Gyn Setting

A Study to Learn About a Combined COVID-19 and Influenza Shot in Healthy Adults

The Effect of a Planning Prompt on Seasonal Influenza Vaccination Rates

Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu)

Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza

Study to Collect Sera for Immunogenicity Testing in Children Vaccinated With Fluzone®

A Pragmatic Assessment of Influenza Vaccine Effectiveness in the DoD

Safety of and Immune Response to a Bird Flu Virus Vaccine (H5N1) in Healthy Adults

Study to Evaluate the Safety and Immunogenicity of KBP-V001 Quadrivalent Influenza Vaccine in Healthy Adults

Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Monovalent Pandemic H5N1 Vaccine in Adults

A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults

Blood and Plasma Collection For Use in Future Clinical Trials

Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older

D2560C00015 FluMist Annual Safety Study 2018

FINDER® Instrument and FINDER® FLU A/B, RSV, SARS-CoV-2 Test Clinical Evaluation Protocol